NabGen Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $3M

  • Investors
  • 3

NabGen General Information

Description

Operator of a biotechnology company developing a novel strategy to block AAV-neutralizing universal antibody suppressant as a therapeutic to inhibit anti-drug antibodies,anti-transplant antibodies, and treat autoimmune disease. The company's platform technology functions as a universal antibody suppressant to inhibit anti-drug antibodies, and anti-transplant antibodies, and treat autoimmune disease and offers a strategy to block AAV (adeno-associated virus)-neutralizing antibody activity and re-administration barriers of gene therapies based on adeno-associated virus AAV vectors, enabling doctors to unlock the full potential of cutting-edge treatments for patients with rare diseases.

Contact Information

Website
www.nabgen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6 Davis Drive
  • Durham, NC 27709
  • United States
+1 (919)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 6 Davis Drive
  • Durham, NC 27709
  • United States
+1 (919)

NabGen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NabGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 15-Aug-2025 $3M Completed Generating Revenue
5. Grant 31-Mar-2023 Completed Generating Revenue
4. Early Stage VC 10-Mar-2022 Completed Startup
3. Debt - General 29-Jul-2021 Completed Startup
2. Grant 31-Jul-2020 $300K $30K Completed Startup
1. Accelerator/Incubator 21-May-2020 $30K $30K Completed Startup
To view NabGen’s complete valuation and funding history, request access »

NabGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company developing a novel strategy to block AAV-neutralizing universal antibody suppressant
Drug Discovery
Durham, NC
4 As of 2026

Lund, Sweden
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NabGen Competitors (3)

One of NabGen’s 3 competitors is Hansa Biopharma, a Corporation company based in Lund, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Hansa Biopharma Corporation Lund, Sweden
Selecta Biosciences Formerly VC-backed Watertown, MA
Argenx Formerly VC-backed Zwijnaarde, Belgium
You’re viewing 3 of 3 competitors. Get the full list »

NabGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NabGen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Center For Advancing Translational Sciences Government
National Institute Of Allergy and Infectious Diseases Government
KickStart Venture Services Accelerator/Incubator
To view NabGen’s complete investors history, request access »

NabGen FAQs

  • When was NabGen founded?

    NabGen was founded in 2019.

  • Where is NabGen headquartered?

    NabGen is headquartered in Durham, NC.

  • What is the size of NabGen?

    NabGen has 4 total employees.

  • What industry is NabGen in?

    NabGen’s primary industry is Drug Discovery.

  • Is NabGen a private or public company?

    NabGen is a Private company.

  • What is NabGen’s current revenue?

    The current revenue for NabGen is .

  • How much funding has NabGen raised over time?

    NabGen has raised $780K.

  • Who are NabGen’s investors?

    National Center For Advancing Translational Sciences, National Institute Of Allergy and Infectious Diseases, and KickStart Venture Services have invested in NabGen.

  • Who are NabGen’s competitors?

    Hansa Biopharma, Selecta Biosciences, and Argenx are competitors of NabGen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process